secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2022-10-17T23:59:59+00:00
Accession:  0001193125-22-263403
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva Neurosciences receives FDA refusal to file for roluperidone NDA in schizophrenia negative symptoms
--------------------------------------------------------------------------------

- FDA issued Refusal to File letter for NDA of roluperidone for negative symptoms of schizophrenia.
- No approved therapies exist in US for negative symptoms of schizophrenia; company disappointed.
- Company intends to request a Type A meeting to discuss the refusal to file letter.
- Roluperidone is a clinical-stage therapy; NDA submission not accepted by FDA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312522263403/0001193125-22-263403-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312522263403/d370453d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-263403

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer